Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$0.37.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) rose 6542.06% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 5314.14%. This contributed to the annual value of -$4.43 for FY2024, which is 73285.71% down from last year.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.37 in Q3 2025, which was up 6542.06% from -$0.46 recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $0.31 during Q2 2023, and its lowest value of -$4.15 during Q4 2021.
- Over the past 5 years, Amylyx Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$0.77 (recorded in 2022), while the average stood at -$1.08.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 13333.33% in 2023, then crashed by 885000.0% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$4.15 in 2021, then surged by 85.06% to -$0.62 in 2022, then soared by 111.29% to $0.07 in 2023, then crashed by 871.43% to -$0.54 in 2024, then soared by 31.48% to -$0.37 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.37 in Q3 2025, compared to -$0.46 in Q2 2025 and -$0.42 in Q1 2025.